To determine the feasibility of using splenic cDCs for adoptive transfer experiments and to explore potential differences between cDCs of naïve and FLT-3 ligand-secreting tumor mice, we assessed CXCR4 expression and the maturation status of splenic cDCs. The gene discussed is FLT3; the disease is neoplasm.